Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2025-12-09 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
董事、高级管理人员所持公司股份及其变动管理制度（2025年12月）
Director's Dealing Classification · 95% confidence The document is titled '董事、高级管理人员所持公司股份及其变动管理制度' which translates to 'Management System for Shares Held and Changes by Directors and Senior Management'. It details rules and procedures regarding the holding, buying, selling, reporting, locking, and disclosure of shares by company directors and senior management. It references relevant laws and regulations, outlines restrictions on share transactions, reporting obligations, and internal management responsibilities. There is no financial data, earnings information, or report publication mentioned. The content is focused on governance and internal rules related to directors' shareholdings and their changes. This fits the category of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives and related management rules. The document is comprehensive and regulatory in nature, not a simple announcement or a report publication. Therefore, the classification is DIRS with high confidence.
2025-12-09 Chinese
信息披露暂缓与豁免制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled '信息披露暂缓与豁免制度' which translates to 'Information Disclosure Delay and Exemption System'. It outlines the company's internal policies and procedures regarding the delay and exemption of information disclosure, including legal references, internal approval processes, and record-keeping requirements. It is a governance-related document detailing how the company manages disclosure obligations and compliance with regulatory requirements. There is no financial data, no report of financial results, no announcement of voting results, no legal proceeding update, no capital or financing update, and no other specific filing content. The document is a governance policy document issued by the company's board, focusing on internal rules and governance practices related to information disclosure. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2770 characters, which is relatively short but contains substantive governance content, not just an announcement or certification, so it is not RPA or RNS.
2025-12-09 Chinese
董事、高级管理人员离职管理制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled '董事、高级管理人员离职管理制度' which translates to 'Board and Senior Management Departure Management System'. It outlines policies and procedures related to the resignation, termination, and post-departure obligations of directors and senior management personnel. The content focuses on governance rules, responsibilities, and compliance with laws and company bylaws. There is no financial data, earnings information, or report publication mentioned. It is a governance-related internal policy document rather than a report or announcement. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2315 characters, indicating it is a full policy document rather than a brief announcement.
2025-12-09 Chinese
股东会议事规则（2025年12月）
Governance Information Classification · 100% confidence The document is titled '股东会议事规则' which translates to 'Rules of Procedure for Shareholders' Meetings' for Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the procedures, rights, and regulations governing the conduct of shareholders' meetings, including annual and extraordinary meetings, voting rights, proposal submissions, meeting notices, and legal compliance. It does not contain financial statements, audit opinions, or earnings data. Instead, it is a governance document outlining internal rules and procedures related to shareholder meetings. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, so it is not an RPA or RNS.
2025-12-09 Chinese
董事会审计委员会工作细则（2025年12月）
Governance Information Classification · 95% confidence The document is titled '董事会审计委员会工作细则' which translates to 'Board Audit Committee Working Rules'. It details the structure, responsibilities, and procedures of the audit committee within the board of directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. The content focuses on governance, audit oversight, internal control supervision, and committee meeting rules. There is no financial data, no financial statements, no earnings information, no voting results, no legal proceedings, no capital changes, or other report types. It is a governance-related document outlining internal rules and committee functions. Therefore, it fits best under Governance Information (CGR). The document length is about 5295 characters, which is sufficient for a detailed governance document, not a mere announcement or certification.
2025-12-09 Chinese
独立董事专门会议制度（2025年12月）
Governance Information Classification · 95% confidence The document is titled '独立董事专门会议制度' which translates to 'Independent Directors Special Meeting System'. It details the rules, responsibilities, and procedures for independent directors' meetings within the company. The content focuses on governance practices, meeting protocols, voting rights, and the role of independent directors in oversight and decision-making. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document outlining internal rules and board structure. Therefore, it fits best under Governance Information (CGR). The document length is 4153 characters, which is consistent with a detailed governance policy rather than a brief announcement or a full financial report.
2025-12-09 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.